cPLA₂α
Phase I/II data strengthens Coegin Pharma
The first reading from Coegin Pharma's COAK Phase I/II study in actinic keratosis has produced positive results. Top-line data indicate...
Intervju
Coegin Pharma about to start the COAK study
Nordic biotechnology company Coegin Pharma reached an important...
Intervju
Coegin Pharma's journey from concept to clinic
Thirty years of groundbreaking research aimed at...
Coegin Pharma – value creation and risk reduction in 2021
With the 2020 annual report, Coegin Pharma sets its...
Coegin Pharma applies for clinical trial start
There is a high demand for innovative treatments for...
Coegin Pharma expands its investment
Coegin Pharma, which is developing a new method for...
Coegin Pharma's clinical development in actinic keratosis
Actinic keratosis is one of the most common skin diseases...
Intervju
Coegin Pharma has a new vision for cancer treatment
Nordic biotech company Coegin Pharma responds to demand for new...
Intervju
Current situation analysis Coegin Pharma – A new approach to cancer therapy
Nordic biotech company Coegin Pharma is responding to the need...